Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka
Managing Director, Dr Rajen Manicka
Sourced: The Edge Markets
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Holista CollTech (HCT) has appointed Health Therapies as its exclusive distributor in the U.S. for its NatShield hand sanitiser
  • Health Therapies has exclusive access to the U.S. market for three years
  • It has committed to a minimum spend order of at least A$3 million per year.
  • A shipment of the first 5000 bottles of NatShield will be coming from Malaysia this week
  • Holista is now in discussions to introduce NatShield to more countries
  • The company is also developing online capabilities to better deliver NatShield
  • Holista shares are up a steady 16.3 per cent on the market today and are currently trading for 10 cents each

Holista CollTech (HCT) has appointed Health Therapies LLC as its exclusive distributor in the United States for NatShield.

Health Therapies has exclusive access to the U.S. market for three years and has committed to a minimum spend order of at least AUD$3 million per year.

The orders are for Holista’s NatShield hand sanitisers, which contain Path-Away — a plant-based, active ingredient.

Path-Away is used in Holista’s NatShield sanitising spray. It works by crippling a virus’ cell walls, causing bacteria to group together and destroy themselves within seconds.

In mid-March, Holista began testing Path-Away’s effectiveness against COVID-19. These tests are expected to be completed before the end of next month and results are expected within two to three weeks thereafter.

This testing will be completed in tandem with Global Infections Control Consultants LLC (GICC LLC).

A shipment of the first 5000 bottles of NatShield will be coming from Malaysia this week. Holista plans to bottle NatShield within the United States by next month.

“The appointment of a U.S. distributor is timely because of the escalating rate in the country. We are shipping sanitises out of Malaysia initially to meet the urgent needs,” Holista CEO Dr Rajen Manicka said.

“Discussions have begun with U.S. bottlers who, part of the logistic supply chain of GICC LLC, can commit to up to one million bottles per month with capacity to scale further,” he added.

Discussions are now underway on a number of further significant distribution and supply arrangements which, when finalised, will have an immediate effect of introducing NatShield to more countries.

Holista is also developing online capabilities to better deliver NatShield as needed.

With the global outbreak of COVID-19, Holista is also pleased to be in a stronger financial position after recently raising $4.33 million. This cash will help the company meet the global demand.

Holista shares are up a steady 16.3 per cent on the market in mid-morning trade and are trading for 10 cents each at 11:17 am AEDT.

HCT by the numbers
More From The Market Online

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.

PharmAust CEO’s sayanora triggers stock plunge

Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of…

Recce wins safety board approval to dose 4g in R327 UTI infusion trial

Recce Pharma will dose patients with 4g of its R327 intravenous solution to treat UTIs in…

Emyria locks in $2.3M to progress MDMA research – with Chair adding $0.3M

WA-based and ASX-listed Emyria is seeking to further research using MDMA to treat PTSD. The chair…